Liquidia Corporation's YUTREPIA launch drives rapid revenue growth and profitability

Earnings
โดย Yahoo Finance·Read original
Summary · why it matters

Liquidia Corporation has scaled annualized revenue from virtually zero to approximately $520 million within three full quarters of launching YUTREPIA for pulmonary hypertension, with quarterly revenue climbing from $8.8 million to $132.9 million. Roughly 75% of new patient starts are treatment-naive, indicating market expansion rather than just competitor displacement. EBITDA improved from substantial losses to approximately $61.9 million, with a 54% margin in the third quarter post-launch, and net income turned strongly positive while gross margins remained above 90%. Management guides toward approximately $1 billion of revenue in 2027, supported by a new manufacturing facility in 2026 that will triple capacity, and the company has an estimated $6 billion addressable market. Key risks include ongoing litigation from United Therapeutics and potential moderation of launch growth as penetration increases.

Impact on stocks 4

Biotech & Genomic Medicine± Mixed · 4 stocks
Liquidia Technologies Inc
LQDA
▲ PositiveDemandrelevance

YUTREPIA launch drives rapid revenue growth and profitability, with 75% of new patient starts being treatment-naive, indicating market expansion

United Therapeutics Corporation
UTHR
▼ NegativeCompetitionrelevance

Liquidia's YUTREPIA is competing with United Therapeutics' products, and ongoing litigation from United Therapeutics is noted as a key risk for Liquidia

© 2026 MarketDXNews